ReviewCurrent hypertension reports2014
Resistant or refractory hypertension: are they different?
Review in Current hypertension reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06450327 (Resistant Hypertension An Open, Complicated), which is not on this map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Resistant Hypertension An Open, Complicated ("Cum Plicare") or Complex ("Cum Plexus")
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Refractory Hypertension: a Narrative Systematic Review with Emphasis on Prognosis.Current hypertension reports · 2022Pooled it
- Predictors of Renal Denervation Efficacy in the Treatment of Resistant Hypertension.Current hypertension reports · 2015Trial
- Prevalence and clinical profile of refractory hypertension in a large cohort of patients with resistant hypertension.Journal of human hypertension · 2021Article
- Refractory hypertension: what do we know so far?Journal of human hypertension · 2021Article
- [Therapy-resistant and therapy-refractory arterial hypertension].Der Internist · 2018Article
- Controlled Versus Uncontrolled Resistant Hypertension: Are They in the Same Bag?Current hypertension reports · 2018Review
- Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists.Vascular health and risk management · 2017Review
- Brazilian Position Statement on Resistant Hypertension - 2020.Arquivos brasileiros de cardiologiaArticle
- Resistant and refractory hypertension: two sides of the same disease?Jornal brasileiro de nefrologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resistant hypertension (RHTN) consists in a condition where blood pressure (BP) levels remain uncontrolled despite the use of at least three drugs or if the control happens with four or more drugs. Throughout the last 50 years, it has been increasingly studied, and its phenotypes have been identified. The term refractory hypertension has been used concurrently with RHTN all those years, but in the last decade, it has been applied to the most afflicted part of RHTN--defined as the uncontrolled RHTN or as the uncontrolled RHTN who needs five or more drugs. Differences between those two phenotypes are being recently identified, especially classifying refractory subjects as having more: (1) cardiovascular risk, (2) target organ damage, (3) African-descending race, (4) coronary heart disease and myocardial ischemia, (5) aldosterone excess, (6) deregulation of adipokines, and (7) possible sympathetic hyperactivation. We review the most important studies in both resistant and refractory hypertension to gather the up-to-date data regarding the characteristics of these two high-risk groups of patients.
Indexed as
Identifiers
25139782What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.